CII
OMED

CR Intrinsic Investors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

CR Intrinsic Investors’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-270,592
Closed -$4.14M – 460
2013
Q3 		$4.14M Buy
+270,592
New +$5.01M 0.13% 220

Other funds holding OMED

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CR Intrinsic Investors's OMED Position: Q4 2013 in Review

CR Intrinsic Investors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2013, closing a stake of 270,592 shares — an estimated $4.14M sold.

CR Intrinsic Investors first reported a position in OMED in Q3 2013 and held it in 1 quarter. The position peaked at $4.14M in Q3 2013. 55 funds tracked by Wall St. Rank hold OMED as of Q4 2013.

  • CR Intrinsic Investors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 270,592 OncoMed Pharmaceuticals, Inc. shares in Q4 2013, an estimated $4.14M.
  • CR Intrinsic Investors first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's OncoMed Pharmaceuticals, Inc. position peaked at $4.14M in Q3 2013.
  • 55 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.